TimTaylor06
Comments (15) |+ Follow |Send Message
First, let me say. DWD, I appreciate your rational and that you can have good banter back and forth. Some people are just so biased or butthurt, you can't even have discussions with them. Couple thoughts to your post:
OpEx is only going to be related to the drugs they are developing and overhead - which I don't know how much that will be but as the drugs past different phases it will only increase value of PTN. Second of all, you still aren't taking into consideration the $60 million they got upfront, the $25 million for reimbursements, and the lump sums they get for milestones. I think its up to $300 million or so. I don't want to do the math but that is pretty good money to use to develop their other drugs without having to dilute the stock anymore and will increase their share price.
Also, you HAVE to use the multiplier because that's just business. Positive cash flow from royalties is always measured on a multiplier because its just that, positive cash flow. In a year or so, if Brem is approved, I see it trading in a range of $1-$1.50 until the market reacts to the efficacy of Brem and if they like it or not.
In the near term - leading up to the FDA submission, I think we will climb to low $60'. until beginning of 2018. There's no risk and they have cash now, they will start trials, secure a EU partner (get more cash, maybe $20-$30 million upfront) and penny warrants are almost gone.
Now's the best time to get in and risk for downside is extremely low.
NEW | 20 Jul 2017, 01:22 PM Report Abuse Reply
Quelle:
seekingalpha.com/article/...pt?v=1497801254&comments=show
Zurück
Weiter
